BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst

On Thursday, Truist initiated coverage on BioNTech SE BNTX, a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc PFE.BioNTech is transitioning from a COVID-focused narrative to a story centered on oncology drug development and upcoming catalysts.The analyst, Asthika Goonewardene, writes that BNT327 is at the forefront, a promising drug in an innovative class that could challenge and potentially surpass the PD-1 category, which generated over $42 billion in 2023.Also Read: BioNTech Earns Upgrade ...